Valuation : Silence Therapeutics plc

Market Cap 580M 784M 675M 640M 1.09B 74.89B 1.09B 7.6B 2.92B 38.1B 2.94B 2.88B 120B P/E 2026 *
-24.5x
P/E 2027 * -19.7x
Enterprise Value 447M 604M 520M 493M 838M 57.7B 842M 5.85B 2.25B 29.35B 2.27B 2.22B 92.76B EV / Sales 2026 *
1,385x
EV / Sales 2027 * 540x
Free-Float
69.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Silence Therapeutics plc

1 day-27.27%
1 month-12.57%
3 months+277.36%
6 months+100.00%
Current year+100.00%
1 month 4
Extreme 4
5.5
Current year 1.06
Extreme 1.06
5.99
1 year 1.06
Extreme 1.06
5.99
3 years 0.5
Extreme 0.4986
14.75
5 years 0.5
Extreme 0.4986
46.5
10 years 0.5
Extreme 0.4986
46.5
Manager TitleAgeSince
Chief Executive Officer 72 30/11/2025
Director of Finance/CFO 54 31/01/2022
Chief Tech/Sci/R&D Officer - 31/12/2020
Director TitleAgeSince
Director/Board Member 63 20/06/2018
Chairman 72 31/12/2003
Director/Board Member 65 04/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-27.27%-.--% - - 784M
-0.71%-6.35%-4.87%+9.03% 45.48B
+0.21%-2.98%+340.68%+519.93% 43.69B
+1.74%-2.24%+37.28%+21.57% 43.09B
+1.38%-3.28%+3.23%+65.60% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+18.07%+110.32% 16.4B
-0.31%-2.78%+10.47%+30.49% 14.24B
+1.93%-3.55%+74.20%+39.37% 13.28B
Average -2.29%-3.57%+60.98%+104.14% 29.42B
Weighted average by Cap. +0.33%-3.67%+73.16%+123.57%

Financials

2026 *2027 *
Net sales 322K 436K 376K 356K 605K 41.66M 608K 4.23M 1.62M 21.19M 1.64M 1.6M 66.97M 751K 1.01M 874K 828K 1.41M 96.97M 1.42M 9.83M 3.78M 49.33M 3.81M 3.73M 156M
Net income -42.14M -56.98M -49.1M -46.49M -79.05M -5.44B -79.45M -552M -212M -2.77B -214M -209M -8.75B -71.01M -96.03M -82.74M -78.34M -133M -9.17B -134M -930M -358M -4.67B -361M -353M -14.75B
Net Debt -133M -180M -155M -147M -250M -17.2B -251M -1.74B -671M -8.75B -676M -661M -27.64B -174M -235M -203M -192M -327M -22.49B -328M -2.28B -877M -11.44B -884M -865M -36.15B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.02USD
Average target price
33.00USD
Spread / Average Target
+153.46%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!